Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aryl sulphonyl amides as potent agonists of the growth hormone secretagogue (ghrelin) receptor.
Witherington J, Abberley L, Bellenie BR, Boatman R, Collis K, Dean DK, Gaiba A, King NP, Shuker N, Steadman JG, Takle AK, Sanger G, Butler S, McKay F, Muir A, Winborn K, Ward RW, Heightman TD. Witherington J, et al. Among authors: gaiba a. Bioorg Med Chem Lett. 2009 Feb 1;19(3):684-7. doi: 10.1016/j.bmcl.2008.12.042. Epub 2008 Dec 14. Bioorg Med Chem Lett. 2009. PMID: 19128969
(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: a novel class of potent MSK-1-inhibitors.
Bamford MJ, Alberti MJ, Bailey N, Davies S, Dean DK, Gaiba A, Garland S, Harling JD, Jung DK, Panchal TA, Parr CA, Steadman JG, Takle AK, Townsend JT, Wilson DM, Witherington J. Bamford MJ, et al. Among authors: gaiba a. Bioorg Med Chem Lett. 2005 Jul 15;15(14):3402-6. doi: 10.1016/j.bmcl.2005.05.021. Bioorg Med Chem Lett. 2005. PMID: 15950465
The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.
Takle AK, Brown MJ, Davies S, Dean DK, Francis G, Gaiba A, Hird AW, King FD, Lovell PJ, Naylor A, Reith AD, Steadman JG, Wilson DM. Takle AK, et al. Among authors: gaiba a. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. doi: 10.1016/j.bmcl.2005.09.072. Epub 2005 Nov 2. Bioorg Med Chem Lett. 2006. PMID: 16260133
Pyridone derivatives as potent and selective VLA-4 integrin antagonists.
Witherington J, Bordas V, Gaiba A, Green PM, Naylor A, Parr N, Smith DG, Takle AK, Ward RW. Witherington J, et al. Among authors: gaiba a. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2256-9. doi: 10.1016/j.bmcl.2006.01.025. Epub 2006 Feb 7. Bioorg Med Chem Lett. 2006. PMID: 16455247
Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists.
Witherington J, Blaney EL, Bordas V, Elliott RL, Gaiba A, Garton N, Green PM, Naylor A, Smith DG, Spalding DJ, Takle AK, Ward RW. Witherington J, et al. Among authors: gaiba a. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5538-41. doi: 10.1016/j.bmcl.2006.08.044. Epub 2006 Aug 22. Bioorg Med Chem Lett. 2006. PMID: 16931004
Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation.
Witherington J, Abberley L, Briggs MA, Collis K, Dean DK, Gaiba A, King NP, Kraus H, Shuker N, Steadman JG, Takle AK, Sanger G, Wadsworth G, Butler S, McKay F, Muir A, Winborn K, Heightman TD. Witherington J, et al. Among authors: gaiba a. Bioorg Med Chem Lett. 2008 Mar 15;18(6):2203-5. doi: 10.1016/j.bmcl.2007.12.021. Epub 2007 Dec 15. Bioorg Med Chem Lett. 2008. PMID: 18316188
The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.
Takle AK, Bamford MJ, Davies S, Davis RP, Dean DK, Gaiba A, Irving EA, King FD, Naylor A, Parr CA, Ray AM, Reith AD, Smith BB, Staton PC, Steadman JG, Stean TO, Wilson DM. Takle AK, et al. Among authors: gaiba a. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4373-6. doi: 10.1016/j.bmcl.2008.06.070. Epub 2008 Jun 24. Bioorg Med Chem Lett. 2008. PMID: 18621524
Author Correction: Scalable and robust SARS-CoV-2 testing in an academic center.
Aitken J, Ambrose K, Barrell S, Beale R, Bineva-Todd G, Biswas D, Byrne R, Caidan S, Cherepanov P, Churchward L, Clark G, Crawford M, Cubitt L, Dearing V, Earl C, Edwards A, Ekin C, Fidanis E, Gaiba A, Gamblin S, Gandhi S, Goldman J, Goldstone R, Grant PR, Greco M, Heaney J, Hindmarsh S, Houlihan CF, Howell M, Hubank M, Hughes D, Instrell R, Jackson D, Jamal-Hanjani M, Jiang M, Johnson M, Jones L, Kanu N, Kassiotis G, Kirk S, Kjaer S, Levett A, Levett L, Levi M, Lu WT, MacRae JI, Matthews J, McCoy LE, Moore C, Moore D, Nastouli E, Nicod J, Nightingale L, Olsen J, O'Reilly N, Pabari A, Papayannopoulos V, Patel N, Peat N, Pollitt M, Ratcliffe P, Reis e Sousa C, Rosa A, Rosenthal R, Roustan C, Rowan A, Shin GY, Snell DM, Song OR, Spyer MJ, Strange A, Swanton C, Turner JMA, Turner M, Wack A, Walker PA, Ward S, Wong WK, Wright J, Wu M; Crick COVID-19 Consortium. Aitken J, et al. Among authors: gaiba a. Nat Biotechnol. 2020 Aug;38(8):1000. doi: 10.1038/s41587-020-0623-z. Nat Biotechnol. 2020. PMID: 32681136 Free PMC article.
19 results